September 24, 2024 01:12 PM EDTUpdated 04:07 PM
Pharma
Law

Fed­er­al judge rules against Re­gen­eron's at­tempt to halt Am­gen from launch­ing Eylea biosim­i­lar

Katherine Lewin

News Reporter

Re­gen­eron’s stock $REGN dipped about 4% on Tues­day fol­low­ing a loss in its le­gal bat­tle with Am­gen over com­peti­tors to its block­buster eye treat­ment Eylea …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Wave rides new Phase 2 DMD da­ta as it sets sights on ac­cel­er­at­ed ap­proval

Sanofi hires Mike Quigley as next chief sci­en­tist, in­ter­nal memo says

Up­dat­ed: Gene ther­a­py mak­er blue­bird bio cuts costs again, lays off staff

No­vo Nordisk CEO skep­ti­cal of PBM promis­es in Sen­ate hear­ing on weight loss drug prices

Sam­sara adds three ven­ture part­ners to help steer and ad­vise port­fo­lio com­pa­nies

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times